The Effect Of Giving Anti-osteoporosis Medication After Percutaneous Vertebroplasty To Spinal Vertebral Re-compression Fracture

BackgroundIn recent years, with the problem of aging of the population gradually increased, there are more and more patients suffering from senile osteoporosis, of which spinal vertebral compression fractures are a common complication. With the wide use of percutaneous vertebroplasty and percutaneous kyphoplasty in curing spinal vertebral compression fractures, many patients lift the illness and restore their living skills. However, osteoporosis in patients with pathological constitution has not been fundamentally changed, and other vertebrals still have vertebral compression fracture risk. According to the physiological characteristics of the Chinese Han population, we give patients anti-osteoporosis medication, which radically improve osteoporosis in patients with pathological constitution, and reduce its spinal vertebral re-compression fracture incidence.ObjectiveTo evaluate the effect of anti-osteoporosis medication after percutaneous vertebroplasty or percutaneous kyphoplasty in patients with osteoporotic vertebral compression fracture and to study the incidence of vertebral re-compression fractures.Data SourcesWe reviewed86cases of osteoporosis vertebral compression fractures which were treated with PVP or PKP, and the cases from February,2005to July,2011in the first district Orthopedic surgery (Orthopedic trauma) of QiLu Hospital.MethodsWe selected a series of controlled clinical studies which focus on the specific clinical period after patients with percutaneous vertebroplasty or percutaneous kyphoplasty sugary for osteoporotic vertebral compression fractures to evaluate the effect of anti-osteoporosis medication with Visual Analogue PainScale, Oswestry Disability Index, Bone Mineral Density and vertebral re-compression fracture incidence. The follow-up time was more6months. The local orthopedic surgeon evaluated the overall clinical status of the patients, especially vertebral compression fracture risk, in order to decide whether to give anti-osteoporosis combined drug treatment programs.ResultsThere was not a significant difference of Visual Analogue PainScale, Oswestry Disability Index and Bone Mineral Density between the two groups preoperatively and postoperatively (P>0.05). After surgery and6months later, there was a significant difference of Visual Analogue PainScale, Oswestry Disability Index and Bone Mineral Density between the two groups (P<0.05), there was not a significant difference of vertebral re-compression fracture incidence between male of the two groups (P>0.05), and there was a significant difference of vertebral re-compression fracture incidence between female of the two groups (P<0.05).ConclusionsGiving anti-osteoporosis medication after percutaneous vertebroplasty or percutaneous kyphoplasty can decrease patients’pain degree, improve spiral function and life quality, increase bone mineral density. Whether medication can reduce the incidence of vertebral compression fractures, the effect of female patients with medication is more specific, but for male patients, the effect needs further study. Although a combination of anti osteoporosis drugs can increase the incidence of gastrointestinal complications, giving patients anti-osteoporosis medication is undoubtedly a better choice for the most.